Lysophospholipids are potential biomarkers of ovarian cancer

Rebecca Sutphen, Yan Xu, George D. Wilbanks, James Fiorica, Edward C. Grendys, James P. LaPolla, Hector Arango, Mitchell S. Hoffman, Martin Martino, Katie Wakeley, David Griffin, Rafael W. Blanco, Alan B. Cantor, Yi Jin Xiao, Jeffrey P. Krischer

Research output: Contribution to journalArticle

262 Scopus citations

Abstract

Objective: To determine whether lysophosphatidic acid (LPA) and other lysophospholipids (LPL) are useful markers for diagnosis and/or prognosis of ovarian cancer in a controlled setting. Method: Plasma samples were collected from ovarian cancer patients and healthy control women in Hillsborough and Pinellas counties, Florida, and processed at the University of South Florida H. Lee Moffitt Cancer Center and Research Institute (Moffitt). Case patients with epithelial ovarian cancer (n = 117) and healthy control subjects (n = 27) participated in the study. Blinded LPL analysis, including 23 individual LPL species, was performed at the Cleveland Clinic Foundation using an electrospray ionization mass spectrometry-based method. LPL levels were transmitted to Moffitt, where clinical data were reviewed and statistical analyses were performed. Results: There were statistically significant differences between preoperative case samples (n = 45) and control samples (n = 27) in the mean levels of total LPA, total lysophosphatidylinositol (LPI), sphingosine-1- phosphate (S1P), and individual LPA species as well as the combination of several LPL species. The combination of 16:0-LPA and 20:4-LPA yielded the best discrimination between preoperative case samples and control samples, with 93.1% correct classification, 91.1% sensitivity, and 96.3% specificity. In 22 cases with both preoperative and postoperative samples, the postoperative levels of several LPL, including S1P, total LPA, and lysophosphatidylcholine (LPC) levels and some individual species of LPA and LPC, were significantly different from preoperative levels. Conclusion: LPA, LPI, LPC, and S1P appear useful as diagnostic and prognostic biomarkers of ovarian cancer.

Original languageEnglish (US)
Pages (from-to)1185-1191
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume13
Issue number7
StatePublished - Jul 1 2004

    Fingerprint

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Sutphen, R., Xu, Y., Wilbanks, G. D., Fiorica, J., Grendys, E. C., LaPolla, J. P., Arango, H., Hoffman, M. S., Martino, M., Wakeley, K., Griffin, D., Blanco, R. W., Cantor, A. B., Xiao, Y. J., & Krischer, J. P. (2004). Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiology Biomarkers and Prevention, 13(7), 1185-1191.